United Therapeutics Corporation
1110 Spring Street
256 articles with United Therapeutics Corporation
United Therapeutics Corporation announced its financial results for the first quarter ended March 31, 2018.
United Therapeutics Corporation and SteadyMed Ltd. announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®.
Shares of SteadyMed Ltd. have skyrocketed more than 77 percent in premarket trading today after United Therapeutics announced it will acquire the company for a total of $216 million, including $75 million in contingent consideration.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
United Therapeutics Corporation announced that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Oppenheimer 28th Annual Healthcare Conference in New York City.
United Therapeutics Corporation announces their highest quarterly and annual net revenues ever.
United Therapeutics Announces Settlement of Patent Litigation With Actavis Laboratories FL Relating to Orenitram
Under the Settlement Agreement, United Therapeutics granted to Actavis a license to manufacture and commercialize the generic version of Orenitram described in its ANDA filing in the United States beginning on June 15, 2027.
United Therapeutics Corporation to Report Fourth Quarter and Annual 2017 Financial Results Before the Market Opens on Wednesday, February 21, 2018
United Therapeutics will host a teleconference on Wednesday, February 21, 2018, at 9:00 a.m. Eastern Time.
1/8/2018Just before ringing in the new year, Valeant has managed to resolve another crisis.
Corsair Pharma and United Therapeutics Enter Into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair's intellectual property for the development of treprostinil prodrug formulations.
United Therapeutics Corporation will pay $210M to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.
United Therapeutics today announced that the FDA has granted pediatric exclusivity for Adcirca tablets through May 21, 2018, based on study results submitted by Lilly in response to a written request by the FDA to investigate the use of tadalafil in pediatric patients with Duchenne muscular dystrophy.
United Therapeutics today announced its financial results for the third quarter ended September 30, 2017.
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso Inhalation System
United Therapeutics today announced approval by the FDA of a new inhalation device, called the TD-300/A, for use with Tyvaso (treprostinil) Inhalation Solution (Tyvaso).
United Therapeutics To Report Third Quarter 2017 Financial Results Before The Market Opens On Wednesday, October 25, 2017
United Therapeutics announced today that it will report its third quarter 2017 financial results before the market opens on Wednesday, October 25, 2017.
United Therapeutics Announces Freedom-EV Study Of Orenitram To Continue As Planned Following Interim Analysis
United Therapeutics To Report Second Quarter 2017 Financial Results Before The Market Opens On Thursday, July 27, 2017